Health & Biotech
Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers.
Prescient’s CAR-T and targeted therapies are personalised medicine approaches that aim to improve patient outcomes.
Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Prescient has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
Prescient Therapeutics is working to rapidly expand the application of universal CAR-T therapies, capable of addressing all cancers, including solid tumours.
OmniCAR, a universal CAR-T platform employing technology licensed from UPenn, the pioneer and world leader in CAR-T, as well as Oxford University, will allow unprecedented control and flexibility over current generation CAR-T approaches. It combines the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug.
CellPryme-M is a high-performance platform for enhancing cell therapy manufacturing that results in cell products with superior phenotypes that are longer lasting and more efficacious. It involves a single, rapid step that can be easily accommodated within standard cell manufacturing protocols. CellPryme-M was developed by Prescient in collaboration with the Peter MacCallum Cancer Centre, with Prescient retaining whole ownership of intellectual property.
Further to this, Prescient is working with leading CAR-T innovators to develop other improved CAR-T approaches.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Prescient is well funded as it looks to bring its novel OmniCAR T-cell therapy into clinical trials
News
Here’s what CEOs are hoping to change with their New Year’s resolutions for 2022
News
Waiting for 2022? Here’s a bunch of books CEOs are reading during the holiday break
Health & Biotech
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
Health & Biotech
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
News
CEOs look ahead to three things they’re hoping for in 2022
News
CEOs look back and share their company highlights from 2021
News
CEOs look back and share the most important lesson they learnt in 2021
Health & Biotech
Prescient bolsters board with experienced and leading figures in CAR-T therapy
Health & Biotech
Prescient has some very positive findings to share about its OmniCAR platform’s tumour-killing abilities
Health & Biotech
ASX Health Wrap: Resonance gains ground, with sights set on FDA approval for LiverSmart
Health & Biotech
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
Health & Biotech
Health Kick: Prescient Therapeutics’ YTD share price soars +220% after progress in clinical studies and CAR-T platform
Health & Biotech
Prescient announces key hire as leading US neurosurgeon Donald M O’Rourke joins its Advisory Board
Stockhead TV
90 Seconds With… Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Health & Biotech
Prescient Therapeutics finished the June quarter stronger than ever
Health & Biotech